Related Experiment Video
Updated: Jul 6, 2025

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles
Published on: May 14, 2021
Advancing Precision: A Controllable Self-Synergistic Nanoplatform Initiating Pyroptosis-Based Immunogenic Cell Death
Weiji Qin1, Lei Qiao2, Qian Wang3
1School of Life Sciences, Anhui Medical University, Hefei 230011, P. R. China.
Abstract:
Heterogeneity of the tumor microenvironment (TME) is primarily responsible for ineffective tumor treatment and uncontrolled tumor progression. Pyroptosis-based immunogenic cell death (ICD) therapy is an ideal strategy to overcome TME heterogeneity and obtain a satisfactory antitumor effect. However, the efficiency of current pyroptosis therapeutics, which mainly depends on a single endogenous or exogenous stimulus, is limited by the intrinsic pathological features of malignant cells. Thus, it is necessary to develop a synergistic strategy with a high tumor specificity and modulability. Herein, a synergistic nanoplatform is constructed by combining a neutrophil camouflaging shell and a self-synergistic reactive oxygen species (ROS) supplier-loaded polymer. The covered neutrophil membranes endow the nanoplatform with stealthy properties and facilitate sufficient tumor accumulation. Under laser irradiation, the photosensitizer (indocyanine green) exogenously triggers ROS generation and converts the laser irradiation into heat to upregulate NAD(P)H:quinone oxidoreductase 1, which further catalyzes β-Lapachone to self-produce sufficient endogenous ROS, resulting in amplified ICD outcomes. The results confirm that the continuously amplified ROS production not only eliminates the primary tumor but also concurrently enhances gasdermin E-mediated pyroptosis, initiates an ICD cascade, re-educates the heterogeneous TME, and promotes a systemic immune response to suppress distant tumors. Overall, this self-synergistic nanoplatform provides an efficient and durable method for redesigning the immune system for targeted tumor inhibition.
Insights
This study introduces a novel nanoplatform that enhances pyroptosis immunotherapy by amplifying reactive oxygen species (ROS) production. This approach effectively targets tumor microenvironment heterogeneity and suppresses tumor growth, offering a promising strategy for cancer treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cancer Therapy
Background:
- Tumor microenvironment (TME) heterogeneity limits cancer treatment efficacy.
- Pyroptosis-based immunogenic cell death (ICD) therapy shows promise but faces limitations due to single-stimulus dependency.
- Developing synergistic and tumor-specific therapies is crucial for overcoming treatment resistance.
Purpose of the Study:
- To design a synergistic nanoplatform for enhanced pyroptosis-based ICD therapy.
- To overcome TME heterogeneity and improve antitumor effects.
- To develop a highly specific and modulable cancer treatment strategy.
Main Methods:
- Constructed a nanoplatform with a neutrophil membrane shell and a self-synergistic reactive oxygen species (ROS) supplier.
- Utilized laser irradiation to trigger exogenous ROS generation and heat production.
- Leveraged upregulated NAD(P)H:quinone oxidoreductase 1 to catalyze β-Lapachone for endogenous ROS amplification.
Main Results:
- The nanoplatform demonstrated stealth properties and efficient tumor accumulation.
- Amplified ROS production led to enhanced gasdermin E-mediated pyroptosis and ICD.
- The treatment effectively eliminated primary tumors and suppressed distant tumors by re-educating the TME and promoting systemic immunity.
Conclusions:
- The developed self-synergistic nanoplatform provides an effective strategy for pyroptosis-based ICD therapy.
- This approach addresses TME heterogeneity and enhances antitumor immune responses.
- The nanoplatform offers a durable method for targeted tumor inhibition and immune system redesign.
More Related Videos
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
08:02In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...